# Scandinavian Association of Urology Collaboration Group for Renal Cancer

## The Nordic Renal Cancer Group (NORENCA)

Biannual report 2017-2019:

The NORENCA group is a collaboration group, and was established in Malmö in 2015. The focus has been on establishing a well-functioning scientific collaboration and working among the Scandinavian countries.

## Meetings:

2017, November 30<sup>th</sup>- 1<sup>th</sup> December, Steningevik, Sweden

December 10<sup>th</sup>, Arlanda, Sverige

Januar 24<sup>th</sup> -Skype meeting (protocol discussion)

Mai 9<sup>th</sup> – Skype meeting (protocol discussion)

June 20197 – Reykjavik, Island (in conjunction with the 32 NUF congress)

#### Representation:

Sweden: Pernilla Sundquist, Börje Ljungberg

Finland: Harri Nisen, Petrus Järvinen

Denmark: Lars Lund, Ness Azawi

Norway: Frode Nilsen, Christian Beisland

Iceland: Eirikur Gudmundsson

Board: Chair: Lars Lund (elected dec 2018 for 4 years)

Vice-Chair: Harry Nisen (elected dec 2018 for 4 years)

3rd boardmember: Nessn Azawi (elected may 2019 for 4 years)

Web site: http://nuf.nu/collaboration%20groups/NoRenCa.html

#### **Studies:**

1) The NORENCA II study is a questionnaire based study looking into the use of prophylaxis for venous thromboembolism in the Nordic Countries

Lund L, Nisen H, Järvinen P, Fovaeus M, Gudmundsson E, Kromann-Andersen B, Ljungberg B, Nilsen F, Sundqvist P, Clark PE, Beisland C. Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study). Res Rep Urol. 2018 Oct 25;10:181-187. doi: 10.2147/RRU.S177774. eCollection 2018. PMID: 30464929

2) A survey to see whether the prophylaxis has changed will presents at the 32 NUF meeting.

Further studies are under discussion and planning.

1) Prospective Multicenter Study Comparing Surgery vs Active Surveillance In Patients With Bosniak 3 Renal Cyst. Principal investigator: Harry Nisen.

Scientific meetings:

The NORENCA will host 1st Nordic advanced renal cancer surgery course at Herlev Hospital, DK the 25<sup>th</sup> and 26<sup>th</sup>, November, 2019

Lars Lund (Chair)